AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
COMPLIANCE WITH RESTRICTIONS ON THE SUBSIDIZED USE OF PROTON PUMP INHIBITORS IN AUSTRALIA
Authors: MCMANUS P MARLEY J BIRKETT DJ LINDNER J
Citation: P. Mcmanus et al., COMPLIANCE WITH RESTRICTIONS ON THE SUBSIDIZED USE OF PROTON PUMP INHIBITORS IN AUSTRALIA, British journal of clinical pharmacology, 46(4), 1998, pp. 409-411
CYTOCHROME P4502C9 - AN ENZYME OF MAJOR IMPORTANCE IN HUMAN DRUG-METABOLISM
Authors: MINERS JO BIRKETT DJ
Citation: Jo. Miners et Dj. Birkett, CYTOCHROME P4502C9 - AN ENZYME OF MAJOR IMPORTANCE IN HUMAN DRUG-METABOLISM, British journal of clinical pharmacology, 45(6), 1998, pp. 525-538
BACULOVIRUS-MEDIATED EXPRESSION OF CYTOCHROME P4502C8 AND HUMAN NADPH-CYTOCHROME P450 REDUCTASE - OPTIMIZATION OF PROTEIN EXPRESSION
Authors: ONG CE MINERS JO BIRKETT DJ BHASKER CR
Citation: Ce. Ong et al., BACULOVIRUS-MEDIATED EXPRESSION OF CYTOCHROME P4502C8 AND HUMAN NADPH-CYTOCHROME P450 REDUCTASE - OPTIMIZATION OF PROTEIN EXPRESSION, Xenobiotica, 28(2), 1998, pp. 137-152
PRESCRIPTION USE BY PATIENTS WITH CONCESSION CARDS
Authors: MCMANUS P BIRKETT DJ MANT A
Citation: P. Mcmanus et al., PRESCRIPTION USE BY PATIENTS WITH CONCESSION CARDS, Medical journal of Australia, 169(5), 1998, pp. 285-286
LOCALIZATION OF ARYL SULFOTRANSFERASE EXPRESSION IN HUMAN TISSUES USING HYBRIDIZATION HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY
Authors: WINDMILL KF CHRISTIANSEN A TEUSNER JT BHASKER CR BIRKETT DJ ZHU XY MCMANUS ME
Citation: Kf. Windmill et al., LOCALIZATION OF ARYL SULFOTRANSFERASE EXPRESSION IN HUMAN TISSUES USING HYBRIDIZATION HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY, Chemico-biological interactions, 109(1-3), 1998, pp. 341-346
ALLELIC AND FUNCTIONAL VARIABILITY OF CYTOCHROME P4502C9
Authors: BHASKER CR MINERS JO COULTER S BIRKETT DJ
Citation: Cr. Bhasker et al., ALLELIC AND FUNCTIONAL VARIABILITY OF CYTOCHROME P4502C9, Pharmacogenetics, 7(1), 1997, pp. 51-58
ALLELIC AND FUNCTIONAL VARIABILITY OF CYTOCHROME P4502C9
Authors: BHASKER CR MINERS JO COULTER S BIRKETT DJ
Citation: Cr. Bhasker et al., ALLELIC AND FUNCTIONAL VARIABILITY OF CYTOCHROME P4502C9, Pharmacogenetics, 7(1), 1997, pp. 51-58
EVIDENCE FOR INVOLVEMENT OF HUMAN CYP3A IN THE 3-HYDROXYLATION OF QUININE
Authors: ZHANG H COVILLE PF WALKER RJ MINERS JO BIRKETT DJ WANWIMOLRUK S
Citation: H. Zhang et al., EVIDENCE FOR INVOLVEMENT OF HUMAN CYP3A IN THE 3-HYDROXYLATION OF QUININE, British journal of clinical pharmacology, 43(3), 1997, pp. 245-252
1-METHYLXANTHINE DERIVED FROM CAFFEINE AS A PHARMACODYNAMIC PROBE OF OXYPURINOL EFFECT
Authors: BIRKETT DJ MINERS JO VALENTE L LILLYWHITE KJ DAY RO
Citation: Dj. Birkett et al., 1-METHYLXANTHINE DERIVED FROM CAFFEINE AS A PHARMACODYNAMIC PROBE OF OXYPURINOL EFFECT, British journal of clinical pharmacology, 43(2), 1997, pp. 197-200
THE ROLE OF THE CYP2C9-LEU(359) ALLELIC VARIANT IN THE TOLBUTAMIDE POLYMORPHISM
Authors: SULLIVANKLOSE TH GHANAYEM BI BELL DA ZHANG ZY KAMINSKY LS SHENFIELD GM MINERS JO BIRKETT DJ GOLDSTEIN JA
Citation: Th. Sullivanklose et al., THE ROLE OF THE CYP2C9-LEU(359) ALLELIC VARIANT IN THE TOLBUTAMIDE POLYMORPHISM, Pharmacogenetics, 6(4), 1996, pp. 341-349
LIMITED VALUE OF THE URINARY PHENYTOIN METABOLIC RATIO FOR THE ASSESSMENT OF CYTOCHROME P4502C9 ACTIVITY IN-VIVO
Authors: TASSANEEYAKUL W BIRKETT DJ PASS MC MINERS JO
Citation: W. Tassaneeyakul et al., LIMITED VALUE OF THE URINARY PHENYTOIN METABOLIC RATIO FOR THE ASSESSMENT OF CYTOCHROME P4502C9 ACTIVITY IN-VIVO, British journal of clinical pharmacology, 42(6), 1996, pp. 774-778
PHARMACODYNAMICS OF OXYPURINOL AFTER ADMINISTRATION OF ALLOPURINOL TOHEALTHY-SUBJECTS
Authors: GRAHAM S DAY RO WONG H MCLACHLAN AJ BERGENDAL L MINERS JO BIRKETT DJ
Citation: S. Graham et al., PHARMACODYNAMICS OF OXYPURINOL AFTER ADMINISTRATION OF ALLOPURINOL TOHEALTHY-SUBJECTS, British journal of clinical pharmacology, 41(4), 1996, pp. 299-304
THE USE OF CAFFEINE AS A METABOLIC PROBE FOR HUMAN DRUG-METABOLIZING-ENZYMES
Authors: MINERS JO BIRKETT DJ
Citation: Jo. Miners et Dj. Birkett, THE USE OF CAFFEINE AS A METABOLIC PROBE FOR HUMAN DRUG-METABOLIZING-ENZYMES, General pharmacology, 27(2), 1996, pp. 245-249
PATTERN OF NONSTEROIDAL ANTIINFLAMMATORY DRUG-USE IN AUSTRALIA 1990-1994 - A REPORT FROM THE DRUG UTILIZATION SUB-COMMITTEE OF THE PHARMACEUTICAL BENEFITS ADVISORY-COMMITTEE
Authors: MCMANUS P PRIMROSE JG HENRY DA BIRKETT DJ LINDNER J DAY RO
Citation: P. Mcmanus et al., PATTERN OF NONSTEROIDAL ANTIINFLAMMATORY DRUG-USE IN AUSTRALIA 1990-1994 - A REPORT FROM THE DRUG UTILIZATION SUB-COMMITTEE OF THE PHARMACEUTICAL BENEFITS ADVISORY-COMMITTEE, Medical journal of Australia, 164(10), 1996, pp. 589-592
PHARMACEUTICAL BENEFITS ADVISORY-COMMITTEE - SOME QUESTIONS - REPLY
Authors: BIRKETT DJ
Citation: Dj. Birkett, PHARMACEUTICAL BENEFITS ADVISORY-COMMITTEE - SOME QUESTIONS - REPLY, Medical journal of Australia, 164(1), 1996, pp. 52-52
HUMAN CYTOCHROME-P450 ISOFORM SPECIFICITY IN THE REGIOSELECTIVE METABOLISM OF TOLUENE AND O-XYLENE, M-XYLENE AND P-XYLENE
Authors: TASSANEEYAKUL W BIRKETT DJ EDWARDS JW VERONESE ME TASSANEEYAKUL W TUKEY RH MINERS JO
Citation: W. Tassaneeyakul et al., HUMAN CYTOCHROME-P450 ISOFORM SPECIFICITY IN THE REGIOSELECTIVE METABOLISM OF TOLUENE AND O-XYLENE, M-XYLENE AND P-XYLENE, The Journal of pharmacology and experimental therapeutics, 276(1), 1996, pp. 101-108
CYTOCHROME P450, 1A2, AND 2C9 ARE RESPONSIBLE FOR THE HUMAN HEPATIC O-DEMETHYLATION OF R-NAPROXEN AND S-NAPROXEN
Authors: MINERS JO COULTER S TUKEY RH VERONESE ME BIRKETT DJ
Citation: Jo. Miners et al., CYTOCHROME P450, 1A2, AND 2C9 ARE RESPONSIBLE FOR THE HUMAN HEPATIC O-DEMETHYLATION OF R-NAPROXEN AND S-NAPROXEN, Biochemical pharmacology, 51(8), 1996, pp. 1003-1008
MODELING THE MARKET UPTAKE OF NEW DRUGS FOLLOWING LISTING FOR SUBSIDYIN AUSTRALIA - A REPORT FROM THE DRUG-UTILIZATION-SUBCOMMITTEE OF THETRALIAN-PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE
Authors: BIRKETT DJ MCMANUS P
Citation: Dj. Birkett et P. Mcmanus, MODELING THE MARKET UPTAKE OF NEW DRUGS FOLLOWING LISTING FOR SUBSIDYIN AUSTRALIA - A REPORT FROM THE DRUG-UTILIZATION-SUBCOMMITTEE OF THETRALIAN-PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE, British journal of clinical pharmacology, 40(4), 1995, pp. 407-410
HUMAN HEPATIC CYTOCHROME-P450 2C9 CATALYZES THE RATE-LIMITING PATHWAYOF TORSEMIDE METABOLISM
Authors: MINERS JO REES DLP VALENTE L VERONESE ME BIRKETT DJ
Citation: Jo. Miners et al., HUMAN HEPATIC CYTOCHROME-P450 2C9 CATALYZES THE RATE-LIMITING PATHWAYOF TORSEMIDE METABOLISM, The Journal of pharmacology and experimental therapeutics, 272(3), 1995, pp. 1076-1081
DIRECT CHARACTERIZATION OF THE SELECTIVITY OF FURAFYLLINE AS AN INHIBITOR OF HUMAN CYTOCHROMES P450 1A1 AND 1A2
Authors: TASSANEEYAKUL W BIRKETT DJ VERONESE ME MCMANUS ME TUKEY RH MINERS JO
Citation: W. Tassaneeyakul et al., DIRECT CHARACTERIZATION OF THE SELECTIVITY OF FURAFYLLINE AS AN INHIBITOR OF HUMAN CYTOCHROMES P450 1A1 AND 1A2, Pharmacogenetics, 4(5), 1994, pp. 281-284
DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS
Authors: ANDERSSON T MINERS JO VERONESE ME BIRKETT DJ
Citation: T. Andersson et al., DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS, British journal of clinical pharmacology, 38(2), 1994, pp. 131-137
IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM
Authors: ANDERSSON T MINERS JO VERONESE ME BIRKETT DJ
Citation: T. Andersson et al., IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM, British journal of clinical pharmacology, 37(6), 1994, pp. 597-604
IN-VITRO PROGUANIL ACTIVATION TO CYCLOGUANIL BY HUMAN LIVER-MICROSOMES IS MEDIATED BY CYP3A ISOFORMS AS WELL AS BY S-MEPHENYTOIN HYDROXYLASE
Authors: BIRKETT DJ REES D ANDERSSON T GONZALEZ FJ MINERS JO VERONESE ME
Citation: Dj. Birkett et al., IN-VITRO PROGUANIL ACTIVATION TO CYCLOGUANIL BY HUMAN LIVER-MICROSOMES IS MEDIATED BY CYP3A ISOFORMS AS WELL AS BY S-MEPHENYTOIN HYDROXYLASE, British journal of clinical pharmacology, 37(5), 1994, pp. 413-420
NEW USES FOR ALLOPURINOL
Authors: DAY RO BIRKETT DJ HICKS N MINERS JO GRAHAM GG BROOKS PM
Citation: Ro. Day et al., NEW USES FOR ALLOPURINOL, Drugs, 48(3), 1994, pp. 339-344
DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS
Authors: ANDERSSON T MINERS JO BIRKETT DJ
Citation: T. Andersson et al., DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 138-138
Risultati: 1-25 | 26-33